Roseburia intestinalis: Difference between revisions

From MicrobeWiki, the student-edited microbiology resource
No edit summary
No edit summary
Line 32: Line 32:
G+C Content is known to be 42.6% [5]
G+C Content is known to be 42.6% [5]


Two known prophages are found in the commonly researched ''R. intestinalis'' strain, Jekyll and Shimadzu that help the bacteria gain host-phage resistance via horizontal gene transfer [2].  
Two known prophages are found in the commonly researched ''R. intestinalis'' strain L1-82, Jekyll and Shimadzu that help the bacteria gain host-phage resistance via horizontal gene transfer [2].  





Revision as of 16:31, 24 April 2024

This student page has not been curated.

Taxonomic Classification

Domain: Bacteria

Phylum: Bacillota

Class: Clostridia

Order: Lachnospirales

Family: Lachnospiraceae

Genus: Roseburia

Species

Roseburia intestinalis

Other species in Roseburia genus: Roseburia hominis; Roseburia inulinivorans; Roseburia faecis; Roseburia cecicola

Description and Significance

Roseburia intestinalis is a major inhabitant of the human gut microbiome, making up 2.3% of the entire gut microbiome and up to 20% of the bacteria found in the colorectal region [5]. R. intestinalis is a butyrate producer, a short-chain fatty acid that provides an energy source for colon epithelial cells to break down dietary fiber. The main reason for it’s ability to produce butyrate is from the enzyme Butyryl-CoA:acetate CoA transferase, which can transform acetate into butyrate. Butyrate is also known to suppress colon cancer, as it induces histone acetylation on the epithelial cells [1]. Butyrate in healthy colon cells will feed them through beta-oxidation, which is what most healthy epithelial cells prefer. It acts as a natural histone deacetylase enzyme inhibitor, which are enzymes known to lead to oncogene expression and is a factor that leads to colon cancer. As R. intestinalis acts as a natural inhibitor to these HDACs, cancer therapies involving R. intestinalis is on the rise in research. Lack of butyrate production has been associated with diseases such as inflammatory bowel disease and Type 2 diabetes [5]. Live Biotherapeutics Drug Discovery has announced R. intestinalis and the rest of its genus as a Next Generation Probiotic for people with digestive issues to restore their gut health, as butyrate production is a big reason inflammation can be suppressed in the gut [6].

Genome Structure

Genome size: 4.5 Mbp

One circular chromosome

G+C Content is known to be 42.6% [5]

Two known prophages are found in the commonly researched R. intestinalis strain L1-82, Jekyll and Shimadzu that help the bacteria gain host-phage resistance via horizontal gene transfer [2].


Cell Structure, Metabolism and Life Cycle

Interesting features of cell structure; how it gains energy; what important molecules it produces.


Ecology and Pathogenesis

Habitat; symbiosis; biogeochemical significance; contributions to environment.
If relevant, how does this organism cause disease? Human, animal, plant hosts? Virulence factors, as well as patient symptoms.

References

[1] Cheng, X., Zhou, T., He, Y., Xie, Y., Xu, Y., & Huang, W. (2022, August 9). The role and mechanism of butyrate in the prevention and treatment of diabetic kidney disease. Frontiers in microbiology.

[2] Cornuault JK, Moncaut E, Loux V, Mathieu A, Sokol H, Petit MA, De Paepe M. The enemy from within: a prophage of Roseburia intestinalis systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition. ISME J. 2020 Mar;14(3):771-787.

[3] Duncan, S. H., Hold, G. L., Barcenilla, A., Stewart, C. S., & Flint, H. J. (2002, September 1). Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. microbiologyresearch.org.

[4] Hillman, E. T., Kozik, A. J., Hooker, C. A., Burnett, J. L., Heo, Y., Kiesel, V. A., Nevins, C. J., Oshiro, J. M. K. I., Robins, M. M., Thakkar, R. D., Wu, S. T., & Lindemann, S. R. (2020, July). Comparative genomics of the genus roseburia reveals divergent biosynthetic pathways that may influence colonic competition among species. Microbial genomics.

[5] Nie, K., Ma, K., Luo, W., Shen, Z., Yang, Z., Xiao, M., Tong, T., Yang, Y., & Wang, X. (2021, November 22). Roseburia intestinalis: A beneficial gut organism from the discoveries in genus and species. Frontiers in cellular and infection microbiology.

[6] Roseburia spp. as next generation probiotics. Live Biotherapeutic. (n.d.).

[7] NCBI genome for Roseburia intestinalis

Author

Page authored by Brianna Ritchey and Fernando Santos, students of Prof. Jay Lennon at Indiana University.